4Vegel F.Intravenous/oral sequential therapy in patients hospitalized with community-acquired pneumonia:which patients,when and what agents?[J].Drugs,2002,62(2):309-317.
5Ramirez JA.Managing antiinfective therapy of community-acquired pneumonia in the hospital setting:focus on switch therapy[J].Pharmacotherapy,2001,21 (7Pt2):79S-82S.
6Omidvari K,de Boisblanc BP,Karam G,et al.Early transition to oral antibiotic therapy for community-acquired pneumonia:duration of therapy,clinical outcomes,and cost analysis[J].Respir Med,1998,92(8):1032-1039.
7Yoshinouchi T, Ohtsuki Y, Fujita J, et al. A study on intraalveolar exudates in acute mycoplasma pneumoniae infection. Acta Med Okayama, 2002, 56 (2): 111-116
8Chu HW, Campbell JA, Rino JG, et al. Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation, and bronchial hyperresponslveness in lungs of mice. J Infect Dis, 2004, 189 (6): 1119-1127
9Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucooorticolds and beta2 agonists on bronchial airway smooth muscle cells through synchronized cellular signaling, Lancet, 2002, 360 (9342) : 1293 ~ 1299
